Log in

NASDAQ:BLUE - bluebird bio Stock Price, Forecast & News

$82.43
+1.98 (+2.46 %)
(As of 02/21/2020 06:00 AM ET)
Today's Range
$80.50
Now: $82.43
$83.48
50-Day Range
$79.69
MA: $89.03
$98.04
52-Week Range
$71.42
Now: $82.43
$163.43
Volume1.16 million shs
Average Volume739,611 shs
Market Capitalization$4.58 billion
P/E RatioN/A
Dividend YieldN/A
Beta2.44
bluebird bio, Inc, a clinical-stage biotechnology company, focuses on developing transformative gene therapies for severe genetic diseases and cancer. Its product candidates in severe genetic diseases include LentiGlobin, which is in various clinical studies for the treatment of transfusion-dependent ß-thalassemia and severe sickle cell disease; and Lenti-D that is in Phase II/III clinical trials for the treatment of cerebral adrenoleukodystrophy, a rare hereditary neurological disorder. Read More…

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:BLUE
CUSIPN/A
Phone339-499-9300

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$44.67 million
Book Value$34.47 per share

Profitability

Net Income$-555,630,000.00
Net Margins-1,767.49%

Miscellaneous

Employees764
Market Cap$4.58 billion
Next Earnings Date5/7/2020 (Estimated)
OptionableOptionable

Receive BLUE News and Ratings via Email

Sign-up to receive the latest news and ratings for BLUE and its competitors with MarketBeat's FREE daily newsletter.


bluebird bio (NASDAQ:BLUE) Frequently Asked Questions

What is bluebird bio's stock symbol?

bluebird bio trades on the NASDAQ under the ticker symbol "BLUE."

How were bluebird bio's earnings last quarter?

bluebird bio Inc (NASDAQ:BLUE) announced its earnings results on Tuesday, February, 18th. The biotechnology company reported ($4.04) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($3.79) by $0.25. The biotechnology company had revenue of $10 million for the quarter, compared to analyst estimates of $8.23 million. bluebird bio had a negative return on equity of 48.54% and a negative net margin of 1,767.49%. The business's revenue for the quarter was down 47.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($2.72) EPS. View bluebird bio's Earnings History.

When is bluebird bio's next earnings date?

bluebird bio is scheduled to release their next quarterly earnings announcement on Thursday, May 7th 2020. View Earnings Estimates for bluebird bio.

What price target have analysts set for BLUE?

20 analysts have issued 12 month price targets for bluebird bio's shares. Their forecasts range from $94.00 to $195.00. On average, they anticipate bluebird bio's stock price to reach $131.52 in the next twelve months. This suggests a possible upside of 59.6% from the stock's current price. View Analyst Price Targets for bluebird bio.

What is the consensus analysts' recommendation for bluebird bio?

20 Wall Street analysts have issued "buy," "hold," and "sell" ratings for bluebird bio in the last year. There are currently 6 hold ratings and 14 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for bluebird bio.

Has bluebird bio been receiving favorable news coverage?

Media headlines about BLUE stock have been trending somewhat positive on Friday, InfoTrie Sentiment reports. InfoTrie scores the sentiment of news coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. bluebird bio earned a coverage optimism score of 1.0 on InfoTrie's scale. They also assigned headlines about the biotechnology company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an effect on the company's share price in the next several days. View News Stories for bluebird bio.

Who are some of bluebird bio's key competitors?

What other stocks do shareholders of bluebird bio own?

Based on aggregate information from My MarketBeat watchlists, some companies that other bluebird bio investors own include Opko Health (OPK), BioMarin Pharmaceutical (BMRN), Puma Biotechnology (PBYI), Celgene (CELG), Incyte (INCY), Medivation (MDVN), NVIDIA (NVDA), Gilead Sciences (GILD), Micron Technology (MU) and ABIOMED (ABMD).

Who are bluebird bio's key executives?

bluebird bio's management team includes the folowing people:
  • Mr. Nick Leschly, Pres, CEO & Director (Age 46)
  • Mr. Jason F. Cole, Chief Operating & Legal Officer and Sec. (Age 46)
  • Dr. Philip D. Gregory, Chief Scientific Officer (Age 48)
  • Mr. Jeffrey T. Walsh, Chief Strategy Officer (Age 53)
  • Dr. David M. Davidson, Chief Medical Officer (Age 55)

Who are bluebird bio's major shareholders?

bluebird bio's stock is owned by a variety of of retail and institutional investors. Top institutional investors include Capital Research Global Investors (12.25%), FMR LLC (11.06%), Capital World Investors (9.52%), Sands Capital Management LLC (5.74%), Victory Capital Management Inc. (3.35%) and Victory Capital Management Inc. (3.30%). Company insiders that own bluebird bio stock include Alison Cecily Finger, David Davidson, James Mandell, Jason Cole, Jeffrey T Walsh, Kory James Wentworth, Mark Vachon, Nick Leschly, Philip D Gregory, Susanna Gatti High and William D Baird III. View Institutional Ownership Trends for bluebird bio.

Which institutional investors are selling bluebird bio stock?

BLUE stock was sold by a variety of institutional investors in the last quarter, including Capital International Investors, Baillie Gifford & Co., FMR LLC, Capital International Inc. CA, Eaton Vance Management, Capital Bank & Trust Co, Bank of America Corp DE and Franklin Resources Inc.. Company insiders that have sold bluebird bio company stock in the last year include Alison Cecily Finger, David Davidson, Jason Cole, Jeffrey T Walsh, Kory James Wentworth, Nick Leschly, Philip D Gregory and William D Baird III. View Insider Buying and Selling for bluebird bio.

Which institutional investors are buying bluebird bio stock?

BLUE stock was bought by a variety of institutional investors in the last quarter, including Sands Capital Management LLC, Casdin Capital LLC, State Street Corp, Victory Capital Management Inc., First Trust Advisors LP, Victory Capital Management Inc., Nikko Asset Management Americas Inc. and Sumitomo Mitsui Trust Holdings Inc.. View Insider Buying and Selling for bluebird bio.

How do I buy shares of bluebird bio?

Shares of BLUE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is bluebird bio's stock price today?

One share of BLUE stock can currently be purchased for approximately $82.43.

How big of a company is bluebird bio?

bluebird bio has a market capitalization of $4.56 billion and generates $44.67 million in revenue each year. The biotechnology company earns $-555,630,000.00 in net income (profit) each year or ($14.31) on an earnings per share basis. bluebird bio employs 764 workers across the globe.View Additional Information About bluebird bio.

What is bluebird bio's official website?

The official website for bluebird bio is http://www.bluebirdbio.com/.

How can I contact bluebird bio?

bluebird bio's mailing address is 60 BINNEY STREET, CAMBRIDGE MA, 02142. The biotechnology company can be reached via phone at 339-499-9300 or via email at [email protected]


MarketBeat Community Rating for bluebird bio (NASDAQ BLUE)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  948 (Vote Outperform)
Underperform Votes:  609 (Vote Underperform)
Total Votes:  1,557
MarketBeat's community ratings are surveys of what our community members think about bluebird bio and other stocks. Vote "Outperform" if you believe BLUE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BLUE will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/21/2020 by MarketBeat.com Staff

Featured Article: What is Cost of Debt?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel